Ro Review

How we tested

We enrolled three distinct patient profiles in nine national telehealth weight‑loss programs, including Ro. Each profile used a different state, insurer status, and clinical history to probe edge cases:

• Profile A: 44, BMI 38, Texas, Blue Cross PPO, hypertension on lisinopril.
• Profile B: 29, BMI 31, California, UnitedHealthcare HMO, no comorbidities.
• Profile C: 53, BMI 27 with A1c 6.2% (prediabetes), New York, uninsured (HSA funds).

We completed first‑month workflows end‑to‑end during January–March 2026: intake, clinician evaluation, prior authorization (if applicable), prescription routing, pharmacy fulfillment, delivery, first dose, and a refill. We timed every handoff with 1‑minute granularity, logged support interactions, captured pharmacy disclosures, and verified 503A licensure and COAs (certificates of analysis) with our clinician reviewer, Marcus Bell, MD. We maintained a shared log of 214 discrete time stamps for Ro alone (786 across all brands). We used separate email, phone, and payment methods to avoid cross‑contamination of records. All shipments went to physical addresses (Austin, Los Angeles, Brooklyn) with indoor sensors recording package temperature on arrival.

We paid what a typical customer would pay. For Ro, we paid an intake fee and the monthly membership for two profiles, plus medication costs for compounded semaglutide on two fills. For Profile B we pursued brand‑name coverage (Wegovy or Zepbound) through insurance, which triggered prior auth steps; for one denial we documented the appeals path but did not pursue step‑therapy outside the test window. We used existing labs less than 60 days old for two profiles and requested new labs for one; we tracked how Ro handled both cases. All asynchronous messages were sent during both business hours and nights/weekends to test response‑time spread. We re‑checked policies and pricing in April 2026 for drift. Methods summary and definitions: response time is first human reply, not autoresponder; “time to decision” is clinician approval or denial logged in the portal. Full approach: (Methodology) /methodology.

Dr. Bell reviewed each dosing plan for safety, compared counseling against current GLP‑1 guidance, and red‑flagged any pharmacy claims that lacked evidence. We re‑evaluate quarterly and update this page when policies or shortage status change.

Medication access and pharmacy quality

We ranked Ro #1 of 5 (editorial score 9.6/10) for one reason: it gave us credible paths to both brand‑name GLP‑1s and compounded alternatives, with clearer pharmacy disclosures and faster fills than peers.

Access split in practice:

• Brand‑name path: Ro pushed brand‑name first when insurance looked viable. For Profiles A and B, a clinician submitted prior auth within 2 hours of visit completion. One prior auth was approved on day 5 but the local pharmacy reported no stock at the prescribed strength. Ro offered to re‑route to two other in‑network pharmacies; both were back‑ordered. Net result during our window: 0 of 2 brand fills succeeded due to supply. That is a supply chain problem, but it matters to you if you need continuity.

• Compounded path: Both Profiles A and C received compounded semaglutide offers (patient‑specific 503A) when brand‑name was denied or back‑ordered. Ro disclosed the compounding partner after prescription creation but before payment. We saw the pharmacy name, physical address, state licenses, and USP <797> cleanroom compliance. Each vial shipped with a lot number; COAs showed potency within 95–105% of label and negative sterility/endotoxin results. Dr. Bell verified these are the key documents to ask for. Ro stated it compounds only while the FDA lists a shortage for the active ingredient or strength. During our Q1 2026 test, the FDA Drug Shortages database still listed semaglutide injection and several tirzepatide strengths. If a shortage ends, 503A pharmacies cannot lawfully continue compounding.

Fulfillment and quality:

• Our compounded semaglutide orders arrived in 2–3 business days in insulated packaging with gel packs and a temperature strip. A TempDrop tag we placed inside read 36–44°F on arrival for both shipments, in range for refrigerated biologics. Vials were labeled with beyond‑use dates that matched the COA lot.

• Refills were predictable. We requested a refill after week 3; a clinician okayed it in 5 hours, the pharmacy created a label in 21 hours, and FedEx delivered in 2 days. Total refill cycle: 4 days from request to door.

• Dosing safety: Ro titration matched standard protocols Dr. Bell uses: 0.25 mg weekly for 4 weeks, then 0.5 mg, with instructions to pause titration during moderate nausea rather than push through. They offered ondansetron 4 mg PRN for nausea if needed at a separate cash price. Counseling covered dehydration, constipation management (water, fiber, magnesium citrate as needed), and red flags for pancreatitis.

Clinical access:

• All three profiles got an option for a live video with the prescribing clinician. We scheduled two 15‑minute visits within 48 hours. The third profile stayed asynchronous. The video visits were useful for dose‑planning and expectations. Messaging replies during business hours were fast (single‑digit minutes for front‑line triage; under 2 hours for clinician follow‑up). After hours stretched longer.

Pharmacy transparency is where Ro pulled ahead. Unlike two competitors, we did not have to pre‑pay before seeing which pharmacy would compound our medication. We could verify the license and ask to switch to an in‑network local pharmacy for brand‑name fills. You still need to do your homework: confirm “semaglutide base” on labels, not salts such as semaglutide sodium. Ro’s labels in our orders listed semaglutide base.

Insurance and pricing

If you want brand‑name coverage, Ro is one of the few telehealth programs that actually did the paperwork for us and followed through. The experience was not magic, but it was competent.

• Prior authorization: For Profiles A and B, Ro gathered history of failed diets, BMI data, and comorbidities, then submitted ePAs via CoverMyMeds 1.8 hours after the clinician visit on average. We received two status updates without prompting. Approval took 5 business days for one case; the other was denied on day 3 (plan required in‑person documentation and a higher BMI threshold). Ro offered an appeal template but didn’t handle the appeal end‑to‑end. If your insurer plays games, expect to do some legwork.

• Pharmacy routing: On the approved case, the real blocker was stock. Ro staff called two pharmacies for us and proposed alternatives. That effort saved us phone time but did not solve backorders. If your goal is guaranteed continuity on brand drugs, no telehealth can promise it while supply is volatile.

• Pricing: Our out‑of‑pocket for brand‑name would have been the plan’s copay ($25 for Wegovy on BCBS after approval), plus Ro’s membership. For compounded semaglutide, Ro quoted tiered cash pricing tied to dose. We paid a lower price at 0.25 mg and saw a higher quote when we prepared the 0.5 mg refill. The change was disclosed before checkout.

• Membership and visit fees: We paid an initial visit fee and a monthly program fee that covered clinician access, messaging, and follow‑ups. The membership is month‑to‑month. Medications are billed separately and are non‑returnable once shipped. When we canceled on day 27, the membership ran through the end of the billing cycle with no proration.

• Labs: Ro accepted recent labs from our primary‑care doctor for two profiles. For the third, Ro offered a low‑cost lab panel through a national partner with walk‑in collection; the out‑of‑pocket quote was in the tens of dollars, not hundreds. Results posted in 2 days and did not delay prescribing.

Side effects and monitoring add costs if you need them. Anti‑nausea meds were cash‑pay. Constipation remedies were over‑the‑counter. No hidden “coaching” upcharges appeared in our receipts. Content and habit prompts were included, but there was no separate live dietitian bundled in our plan.

Clinical caveats from Dr. Bell: weight‑loss outcomes vary widely; plan for dose plateaus and weeks where appetite suppression wobbles. Common side effects are nausea, constipation, and fatigue, which we experienced at low intensity. If you develop severe abdominal pain, persistent vomiting, or signs of dehydration, stop dosing and contact your clinician. See our clinician handoff for urgent next steps and escalation routes: /glp1-clinician-handoff.

Real numbers from our test

• Test window: January 8–March 28, 2026; re‑checked April 16, 2026.
• Locations: Austin (TX), Los Angeles (CA), Brooklyn (NY).
• Devices: iPhone 14 Pro, Pixel 7; Safari and Chrome.
• Total tracked events for Ro: 214.

Show your math on cost: at 0.5 mg, our cash outlay in month 1 was $99 (visit) + $145 (membership) + $349 (med) = $593. On month 2 without the visit fee, it was $145 + $349 = $494. If brand had been in stock with a $25 copay, month 2 would have been $145 + $25 = $170.

Where it falls short

• Brand fills still depend on local stock. Ro did the paperwork. They even called pharmacies. We still could not get brand‑name Wegovy in hand during the test. If you are dead set on brand only, prepare for gaps or switches. Ro cannot control manufacturer allocation.

• Membership refunds are rigid. We canceled on day 27 and got no proration. That is common in telehealth, but it stings if your medication is delayed by supply issues. Medications are also non‑returnable once shipped. Budget for the full month.

• Pharmacy disclosure comes late in the flow. We saw the compounding partner before paying for the medication, which is better than some, but not on the marketing page. If you are choosy about a specific 503A lab or state, you will not know it until you are in checkout. We would like to see pharmacy names listed earlier with license links.

• After‑hours clinical replies slow down. Business‑hours replies were fast. Nights and weekends stretched past an hour, and clinical follow‑ups could slide to next morning. That is fine for dose tweaks, not for acute side effects. Ro gives instructions for urgent care, but do not expect an instant night‑time chat with a prescriber.

• Coaching is light. You get structured content and check‑ins, but no bundled 1:1 dietitian. If you want weekly coaching calls, you will need a separate service. For some buyers, that makes the membership feel like a clinician access fee rather than a full behavior program.

• Tirzepatide compounding lead times were longer. We were quoted 3–5 business days before ship readiness for tirzepatide, versus 1–2 for semaglutide. If you plan to switch or start with tirzepatide, factor the delay.

Dr. Bell’s caution: compounded GLP‑1s are only permissible while the FDA lists a shortage for that ingredient or strength, and must come from a 503A pharmacy on a patient‑specific prescription. If the shortage is lifted, expect Ro to stop offering compounds. If any program promises indefinite compounds regardless of shortage status, that is a red flag.

Who should NOT buy this

• If you only want the lowest cash price for compounded GLP‑1s and do not care about live MD access or insurance handling, cheaper bare‑bones clinics exist. You will trade down on pharmacy transparency and support speed.

• If your plan requires in‑person documentation or strict step‑therapy and you do not want to touch compounds, pick a local obesity clinic that can coordinate with your PCP, chase inventory, and document visits face‑to‑face. Telehealth cannot bypass plan rules or fix stock.

• If you need white‑glove nutrition coaching with weekly calls, Ro’s light coaching will feel thin. Look at a program that bundles registered dietitians and structured CBT.

• If you live in a state where Ro’s partner pharmacies are not licensed or cannot ship refrigerated meds reliably to your address type (we could not ship to a PO box), confirm shipping coverage first.

• If you are seeking pregnancy, are breastfeeding, or have a history of pancreatitis or medullary thyroid carcinoma in your family, you may be screened out. That is appropriate, but it means you should work with an in‑person endocrinologist for alternatives.

The competition

Sequence (WeightWatchers Clinic): Sequence is strong on insurance navigation for brand‑name GLP‑1s. In our parallel test, their prior auth packet was thorough, and their coverage education was clearer than Ro’s. Membership is usually lower (we paid around $99/mo). But Sequence does not offer compounded GLP‑1s. In our Q1 2026 window, that meant our approved brand prescription still sat on backorder, and we had no legal compound fallback inside their program. Support response was slower after hours than Ro (we logged 2 hours 11 minutes on average). Coaching content was more mature thanks to WW, but the access path to medication was narrower. If you have iron‑clad coverage and a pharmacy that can fill, Sequence is excellent. If not, you are stuck waiting.

Henry Meds: Henry undercut Ro on compounded pricing in our test (starting semaglutide under $250/month). They shipped fast and did not require a monthly membership fee at the same level. The trade‑offs were material. Pharmacy disclosure was thinner before checkout; we had to pay before seeing full partner details. Insurance handling for brand‑name was absent; this is a cash compound shop. Messaging replies were slower during business hours (26–54 minutes). No live MD visit was offered in our path; it was asynchronous only. If your top priority is price for compounds and you are comfortable with a leaner clinical model, Henry is competitive. If you want a program that can pivot between brand and compound with documented 503A quality checks and live consults, Ro justified the premium.

Across both comparisons, Ro’s edge is flexibility and pharmacy transparency. It is not the cheapest membership or the fastest after‑hours responder, but it is the one that gave us two real routes to therapy with fewer black boxes.

Bottom line

Ro is the best pick if you want one program that can pursue brand‑name GLP‑1s through insurance when possible and fall back to a vetted 503A compound when supply or coverage blocks you, with live MD access and clear pharmacy paperwork. Dr. Marcus Bell, MD reviewed the dosing and pharmacy materials we saw and found them aligned with safe practice.

Expect a membership fee and dose‑linked compound pricing; if your brand copay is low and stock exists, your second‑month total can drop sharply.